Skip to main content

Recombinant Human CRIM1 Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 1917-CM

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
1917-CM-050

Key Product Details

Source

NS0

Accession #

Conjugate

Unconjugated

Applications

Bioactivity

Product Specifications

Source

Mouse myeloma cell line, NS0-derived human CRIM1 protein
Leu35-Ser939, with a C-terminal 6-His tag

Purity

>90%, by SDS-PAGE under reducing conditions and visualized by silver stain.

Endotoxin Level

<1.0 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Leu35

Predicted Molecular Mass

99.9 kDa

SDS-PAGE

125-140 kDa, reducing conditions

Activity

Measured by the ability of the immobilized protein to support the adhesion of NIH-3T3 mouse embryonic fibroblast cells. Glienke, J. et al. (2002) Mech. Dev. 119:165.
rhCRIM1 immobilized at 3 μg/mL, 100 μL/well, will mediate >50% NIH3T3 cell adhesion (added at 1 x 105 cells/well).

Formulation, Preparation and Storage

1917-CM
Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution
Reconstitute at 100 μg/mL in PBS.

Reconstitution Buffer Available:
Size / Price
Qty
Loading...
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: CRIM1

Cysteine rich motor neuron 1 (CRIM1) is a type I transmembrane glycoprotein of the chordin-like cysteine-rich repeat (CRR) family of BMP inhibitors (1 - 4). The ~130 kDa, 1036 amino acid (aa) CRIM1 contains a 34 aa signal sequence, a 905 aa extracellular domain (ECD), a 21 aa transmembrane domain and a 76 aa cytoplasmic domain. The ECD includes an N-terminal IGF-binding protein-like motif and six chordin-like von Willebrand C-type CRRs. The ECD can be released from the cell, presumably by proteolytic processing (4). Human CRIM1 ECD shows 88%, 88%, 91%, 86%, 87%, 83% and 72% aa identity with mouse, rat, dog, cow, opossum, chick and zebrafish CRIM1 ECD, respectively. CRIM1 can interact with TGF-beta family ligands, including BMPs 2, 4 and 7, via its CRR domains (4). It binds BMPs intracellularly and antagonizes them by lowering their expression, processing and secretion (4). CRIM1 is expressed in the developing spinal cord in the floor plate and developing motor neurons (1). It is also expressed by perivascular smooth muscle cells and aligns at points of cell-cell contact during endothelial cell capillary formation (2). Endothelial cell expression in vitro appears to be specific to cells that are adherent and growing (2). CRIM1 is also expressed in a spatially and temporally restricted manner in the developing lens, limbs, kidney, teeth and testis (5). Studies where CRIM1 expression is manipulated in developing mouse, chick and zebrafish support its involvement in regulation of vascular and somitic development and organogenesis (5 - 7).

References

  1. Kolle, G. et al. (2000), Mech. Dev. 90:181.
  2. Glienke, J. et al. (2002) Mech. Dev. 119:165.
  3. Abreu, J. G. et al. (2002) Gene 287:39.
  4. Wilkinson, L. et al. (2003) J. Biol. Chem. 278:34181.
  5. Pennisi, D. J. et al. (2007) Dev. Dyn. 236:502.
  6. Kolle, G. et al. (2003) Dev. Dyn. 226:107.
  7. Kinna, G. et al. (2006) Mech. Dev. 123:277.

Long Name

Cysteine Rich Motor Neuron 1 Protein

Alternate Names

S52

Entrez Gene IDs

51232 (Human); 50766 (Mouse)

Gene Symbol

CRIM1

UniProt

Additional CRIM1 Products

Product Documents for Recombinant Human CRIM1 Protein, CF

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Recombinant Human CRIM1 Protein, CF

For research use only

Loading...
Loading...
Loading...